Our study not only characterizes pharmacogene changes in NAFLD, but also provides strong validation evidence, by meta-analysis, that CYP2C19 is downregulated in NAFLD. Here, CYP2C19 is linked to metabolic dysfunction-associated steatotic liver disease.